脑脊液分子与免疫标志物诊断原发性中枢神经系统淋巴瘤(PRICELUS)
在荷兰五家医院前瞻性纳入255例疑似原发性中枢神经系统淋巴瘤患者,验证脑脊液MYD88、IL-10与CXCL13的诊断价值。
核心结论
- 脑脊液MYD88、IL-10和CXCL13在疑似原发性中枢神经系统淋巴瘤患者中具有较高诊断价值,联合检测或可支持无创诊断决策并减少对脑活检的依赖。
研究设计与样本
- 多中心前瞻性队列研究,2021年3月1日至2025年5月1日在荷兰五家医院纳入255例疑似原发性中枢神经系统淋巴瘤的成人患者,采用多变量logistic回归与LASSO回归构建诊断panel并做决策树分析。
主要发现
- 255例患者中50例(20%)诊断为中枢神经系统淋巴瘤,其中44例为原发性、6例为继发性;中位年龄61岁(IQR 52-72),男性171例(67%)、女性84例(33%)。
临床怎么用
- 结果需结合完整临床背景解读,诊断算法与决策树在同一队列内推导,应谨慎应用。
- 在特定临床情境下并经进一步验证后,联合脑脊液标志物检测或可支持无创诊断决策、减少对脑活检的依赖。
局限性
- 诊断算法与决策树在同一队列内推导,尚需外部验证。
- 研究仅纳入荷兰五家医院患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary CNS lymphoma is typically diagnosed by brain biopsy, a procedure with risks and diagnostic delay. Emerging cerebrospinal fluid (CSF) biomarkers, including the myeloid differentiation primary response 88 (MYD88) L265P mutation in CSF and several chemokines, might improve diagnostic accuracy, but evidence mostly comes from retrospective, non-consecutive cohorts. We aimed to validate the diagnostic utility of CSF biomarkers in patients with suspected primary CNS lymphoma. METHODS: Patients with suspected primary CNS lymphoma (aged ≥18 years) who underwent CSF analysis were enrolled in five hospitals in the Netherlands between March 1, 2021, and May 1, 2025. Analyses focused on MYD88 and chemokines with reported diagnostic value. A diagnostic panel was constructed with multivariable logistic regression and least absolute shrinkage and selection operator (LASSO) regression. We performed decision tree analysis to evaluate performance. FINDINGS: Of 255 patients (median age 61 years [IQR 52-72]; 171 [67%] males and 84 [33%] females), 50 (20%) were diagnosed with CNS lymphoma; 44 had primary CNS lymphoma and six were diagnosed with secondary CNS lymphoma. In univariable analyses, six of seven chemokines showed significant diagnostic value (area under the curve 0·67-0·96). MYD88 was detected in 28 (56%) of 50 patients with CNS lymphoma, with a sensitivity of 56·0% (95% CI 41·3-70·0) and specificity of 98·5% (198 of 201; 95% CI 95·7-99·7). In the multivariable logistic regression model, MYD88, interleukin-10 (IL-10), and C-X-C motif chemokine ligand 13 (CXCL13) remained independently associated with a CNS lymphoma diagnosis. Combining a positive MYD88 result with elevated IL-10 or CXCL13 (or both) yielded a sensitivity of 54·0% (27 of 50; 95% CI 39·3-68·2) with specificity of 100·0% (95% CI 98·2-100·0). A negative result for all three biomarkers provided a negative predictive value of 99·4% (162 of 163). INTERPRETATION: In this prospective, multicentre cohort of patients with suspected primary CNS lymphoma, we validated the high diagnostic value of MYD88, IL-10, and CXCL13. Results should be interpreted within the full clinical context and with caution, as the diagnostic algorithm and decision tree were derived within the same cohort. In selected clinical scenarios and with further validation of these results, combined CSF biomarker testing might support non-invasive diagnostic decision making and reduce reliance on brain biopsy. FUNDING: Stichting Annie van Koeverden.
引用
- van Rooij JLM, Wessels PH, Niers JM, et al. Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study. Lancet Haematol. 2026. PMID: 42242260. doi:10.1016/S2352-3026(26)00098-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。